Norbrook, maker of Thyronorm, has announced the results of a survey of 200 veterinary surgeons in which 92% said that cat owners were finding it easier to treat their pet's hyperthyroidism with a liquid than a tablet.

95% of the vets surveyed by the company reported success treating cats with Thyronorm Oral Solution for Cats, while 89% expected the liquid solution to improve compliance in the management of hyperthyroidism.

93% also said they found Thyronorm gave them an easier way to offer cats a low dose, or an 'in-between' dose, as it can be titrated 'to effect' – meaning the dose of treatment can be varied more easily to suit the individual animal.

Feline hyperthyroid specialist Dr Sarah Caney said she is unsurprised by the survey results: "Treatment is complex for cats needing a low dose, or an ‘in between’ dose, as standard anti-thyroid tablets are only available in a small number of dose sizes and are not designed to be split, halved or quartered. Also, if a cat is on alternating doses, it can be difficult for carers to remember which dose is due today."

Rachel Crowe, Norbrook’s Companion Animal Senior Product Manager, said: "We are delighted that overall 99% of the 200 veterinary surgeons surveyed would recommend Thyronorm in the management of hyperthyroidism, compared to other medical options."

Thyronorm contains 5mg/ml of thiamazole (methimazole). The initial starting dose is 5mg active ingredient per day, split into two doses.

Available in 30ml and 100ml bottles, with an in-use shelf life of six months, Thyronorm is available to order from all UK veterinary wholesalers.